72 related articles for article (PubMed ID: 19897331)
1. LC/MS characterization of impurities and degradation products of a potent antitumor peptidic dimer, CU201.
Wang J; Krishnamoorthi V; Wang E; Yang C; Baptista D; Wu X; Liu M; Gardner M; Elkins P; Hines J; Liu P
J Pharm Biomed Anal; 2010 Mar; 51(4):824-33. PubMed ID: 19897331
[TBL] [Abstract][Full Text] [Related]
2. Combination cancer chemotherapy with one compound: pluripotent bradykinin antagonists.
Stewart JM; Gera L; Chan DC; York EJ; Simkeviciene V; Bunn PA; Taraseviciene-Stewart L
Peptides; 2005 Aug; 26(8):1288-91. PubMed ID: 15878795
[TBL] [Abstract][Full Text] [Related]
3. A validated stability-indicating LC method for acetazolamide in the presence of degradation products and its process-related impurities.
Srinivasu P; Subbarao DV; Vegesna RV; Sudhakar Babu K
J Pharm Biomed Anal; 2010 May; 52(1):142-8. PubMed ID: 20053517
[TBL] [Abstract][Full Text] [Related]
4. Bradykinin-related compounds as new drugs for cancer and inflammation.
Stewart JM; Gera L; Chan DC; Bunn PA; York EJ; Simkeviciene V; Helfrich B
Can J Physiol Pharmacol; 2002 Apr; 80(4):275-80. PubMed ID: 12025961
[TBL] [Abstract][Full Text] [Related]
5. Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines by a "biased agonist" mechanism.
Chan D; Gera L; Stewart J; Helfrich B; Verella-Garcia M; Johnson G; Baron A; Yang J; Puck T; Bunn P
Proc Natl Acad Sci U S A; 2002 Apr; 99(7):4608-13. PubMed ID: 11930011
[TBL] [Abstract][Full Text] [Related]
6. Characterization and quantitative determination of impurities in piperaquine phosphate by HPLC and LC/MS/MS.
Dongre VG; Karmuse PP; Ghugare PD; Gupta M; Nerurkar B; Shaha C; Kumar A
J Pharm Biomed Anal; 2007 Jan; 43(1):186-95. PubMed ID: 16916594
[TBL] [Abstract][Full Text] [Related]
7. B-9972 (D-Arg-[Hyp3,Igl5,Oic7,Igl8]-bradykinin) is an inactivation-resistant agonist of the bradykinin B2 receptor derived from the peptide antagonist B-9430 (D-Arg-[Hyp3,Igl5,D-Igl7,Oic8]-bradykinin): pharmacologic profile and effective induction of receptor degradation.
Bawolak MT; Gera L; Morissette G; Stewart JM; Marceau F
J Pharmacol Exp Ther; 2007 Nov; 323(2):534-46. PubMed ID: 17699739
[TBL] [Abstract][Full Text] [Related]
8. Correlation of secondary structures of bradykinin B1 receptor antagonists with their activity.
Miskolzie M; Gera L; Stewart JM; Kotovych G
J Biomol Struct Dyn; 2002 Feb; 19(4):585-93. PubMed ID: 11843620
[TBL] [Abstract][Full Text] [Related]
9. LC and LC-MS/MS study of forced decomposition behavior of anastrozole and establishment of validated stability-indicating analytical method for impurities estimation in low dose anastrozole tablets.
Reddy YR; Nandan SR; Bharathi DV; Nagaraju B; Reddy SS; Ravindranath LK; Rao VS
J Pharm Biomed Anal; 2009 Oct; 50(3):397-404. PubMed ID: 19541446
[TBL] [Abstract][Full Text] [Related]
10. Identification, isolation and characterization of impurities of clindamycin palmitate hydrochloride.
Bharathi Ch; Jayaram P; Sunder Raj J; Saravana Kumar M; Bhargavi V; Handa VK; Dandala R; Naidu A
J Pharm Biomed Anal; 2008 Dec; 48(4):1211-8. PubMed ID: 18947955
[TBL] [Abstract][Full Text] [Related]
11. A validated stability-indicating RP-HPLC method for levofloxacin in the presence of degradation products, its process related impurities and identification of oxidative degradant.
Lalitha Devi M; Chandrasekhar KB
J Pharm Biomed Anal; 2009 Dec; 50(5):710-7. PubMed ID: 19632800
[TBL] [Abstract][Full Text] [Related]
12. Determination of duloxetine hydrochloride in the presence of process and degradation impurities by a validated stability-indicating RP-LC method.
Raman NV; Harikrishna KA; Prasad AV; Reddy KR; Ramakrishna K
J Pharm Biomed Anal; 2010 Mar; 51(4):994-7. PubMed ID: 20005658
[TBL] [Abstract][Full Text] [Related]
13. The use of LC/MS, GC/MS, and LC/NMR hyphenated techniques to identify a drug degradation product in pharmaceutical development.
Pan C; Liu F; Ji Q; Wang W; Drinkwater D; Vivilecchia R
J Pharm Biomed Anal; 2006 Feb; 40(3):581-90. PubMed ID: 16242883
[TBL] [Abstract][Full Text] [Related]
14. Isolation and characterization of process related impurities and degradation products of bicalutamide and development of RP-HPLC method for impurity profile study.
Nageswara Rao R; Narasa Raju A; Narsimha R
J Pharm Biomed Anal; 2008 Feb; 46(3):505-19. PubMed ID: 18162355
[TBL] [Abstract][Full Text] [Related]
15. LC-UV-PDA and LC-MS studies to characterize degradation products of glimepiride.
Bansal G; Singh M; Jindal KC; Singh S
J Pharm Biomed Anal; 2008 Nov; 48(3):788-95. PubMed ID: 18804934
[TBL] [Abstract][Full Text] [Related]
16. Identification and characterization of process related impurities in chloroquine and hydroxychloroquine by LC/IT/MS, LC/TOF/MS and NMR.
Dongre VG; Ghugare PD; Karmuse P; Singh D; Jadhav A; Kumar A
J Pharm Biomed Anal; 2009 May; 49(4):873-9. PubMed ID: 19201565
[TBL] [Abstract][Full Text] [Related]
17. [Arg6,D-Trp7,9,NmePhe8]-substance P (6-11) activates JNK and induces apoptosis in small cell lung cancer cells via an oxidant-dependent mechanism.
MacKinnon AC; Armstrong RA; Waters CM; Cummings J; Smyth JF; Haslett C; Sethi T
Br J Cancer; 1999 Jun; 80(7):1026-34. PubMed ID: 10362111
[TBL] [Abstract][Full Text] [Related]
18. Structural modification of the highly potent peptide bradykinin B1 receptor antagonist B9958.
Gera L; Stewart JM; Fortin JP; Morissette G; Marceau F
Int Immunopharmacol; 2008 Feb; 8(2):289-92. PubMed ID: 18182242
[TBL] [Abstract][Full Text] [Related]
19. Applications of hyphenated LC-MS techniques in pharmaceutical analysis.
Ermer J; Vogel M
Biomed Chromatogr; 2000 Oct; 14(6):373-83. PubMed ID: 11002275
[TBL] [Abstract][Full Text] [Related]
20. Bradykinin receptor antagonists containing N-substituted amino acids: in vitro and in vivo B(2) and B(1) receptor antagonist activity.
Goodfellow VS; Marathe MV; Kuhlman KG; Fitzpatrick TD; Cuadrado D; Hanson W; Zuzack JS; Ross SE; Wieczorek M; Burkard M; Whalley ET
J Med Chem; 1996 Mar; 39(7):1472-84. PubMed ID: 8691478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
